BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» GTx Mum as Merck Discontinues Phase II SARM Ostarine/MK-2866
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
GTx Mum as Merck Discontinues Phase II SARM Ostarine/MK-2866
March 5, 2010
By
Trista Morrison
No Comments
Four months after GTx Inc. suffered a devastating FDA setback with lead program toremifene, the biotech's second program - Phase II muscle loss drug Ostarine/MK-2866 - has been discontinued by partner Merck and Co. Inc. (BioWorld Today)
BioWorld